DIEPENBEEK, Belgium, June 3, 2013 /PRNewswire/ --
Amakem NV, a clinical stage ophthalmology company, today announces that Dr. Jack Elands, CEO, will present at the Jefferies 2013 Global Healthcare Conference in New York City.
Dr. Elands will provide a corporate update and information on Amakem's lead drug candidate, the locally-acting Rho kinase (ROCK) inhibitor AMA0076 which is in Phase 2 development for the treatment of glaucoma. The presentation will take place at the Grand Hyatt, New York City at 9.30am Eastern Time on Thursday, June 6.
Based on Amakem's 'Localized Drug Action' platform, AMA0076 is a highly potent ROCK inhibitor that has been designed to enable dosing that maximizes intraocular pressure (IOP) lowering effects, leading to better efficacy, while minimizing side effects such as hyperemia ('red eye'). Hyperemia is seen as a major dose-limiting side effect of other ROCK inhibitors in development.
Amakem is an ophthalmology company developing new treatments for serious eye conditions. Amakem's product pipeline is based on its unique Localized Drug Action platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects. Amakem's lead candidate, AMA0076, is for glaucoma and entered Phase 2a development late last year. The Company is also working to apply the Localized Drug Action approach to a range of other eye diseases.
Founded in 2010, Amakem has raised more than €21m in funding and is backed by leading life sciences investors including Forbion, Omnes Capital (previously Crédit Agricole), Vesalius BioCapital, LRM, PMV/Vinnof and Life Science Research Partners.
Amakem is based in Belgium and located in the life sciences incubator "BioVille" at the University of Hasselt. The Company has a long-standing collaboration with the Ophthalmology Research Center of the University Leuven Hospital, where it sponsors a Chair in Ophthalmology Translational Research.